[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nsclc-stage-i\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nsclc-stage-i":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,40,74,103,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100386884","phase-2-adjuvant-pembrolizumab-vs-observation-following-curative-resection-for-stage-i-non-small-cell-lung-cancer-nsclc-with-primary-tumors-between-1-4-cm-100386884",false,"NCT04317534","Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm","A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153","Inclusion Criteria:\n\n* The participant (or legally acceptable representative if applicable) must provide written informed consent for the study. The participant may also provide consent for future unspecified research samples. However, the participant may participate in the study without participating in the future unspecified research sample collection. NOTE: Initial informed consent will remain valid throughout the 12-week period between surgical resection and study registration unless, in the opinion of the treating investigator, the participant experiences a significant change in medical or mental status.\n* Males and females age ≥ 18 years at the time of consent.\n* ECOG Performance Status of 0-1 within 28 days prior to registration.\n* Patients must have undergone complete surgical resection of their stage I NSCLC between 4-12 weeks prior to registration and have negative surgical margins (R0).\n\n  * NOTE: Both squamous and non-squamous histologies are allowed into the study. Cancers with a histology of \"adenosquamous\" are considered a type of adenocarcinoma and thus \"non-squamous histology\".\n  * NOTE: Staging will be according to the AJCC 8th edition.\n* Pathological tumor size must be 1.0 - 4.0 cm in greatest dimension. NOTE: According to AJCC 8th edition, subjects with lepidic predominant adenocarcinoma should be staged based on their invasive tumor size and not their total tumor size (i.e., subjects with lepidic predominant tumors whose invasive tumor size is less than 1 cm are not eligible, even if their total tumor size is 1.0 cm or greater).\n* Surgery for this lung cancer must be completed at least 28 days prior to registration.\n* Baseline CT chest must be performed within 28 days of randomization to ensure no evidence of disease.\n* Must have either previous NGS and PD-L1 results available using the Dako 22C3 antibody or have archival tissue of surgical specimen from current diagnosis available to perform analyses. PD-L1 results via the Dako 22C3 antibody will be performed per standard of care from a CLIA-accredited laboratory and are required for stratification. If NGS results are not available, subjects must be able to provide at least 10 x 10µm unstained and 1 x 4µm H\\&E slides from current diagnosis for future NGS and\u002For other genetic analyses.\n* Demonstrate adequate organ function as defined in the protocol; all screening labs to be obtained within 28 days prior to registration.\n* Females of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to registration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. For subjects randomized to the pembrolizumab arm: If there is \\> 72 hours between the screening test and C1D1, another pregnancy test (urine or serum) must be performed and must be negative before the subject may start C1D1.\n\n  * NOTE: Females are considered of childbearing potential unless: they are postmenopausal; are surgically sterile; or they have a congenital or acquired condition that prevents childbearing. See Section 5.1.4 for definitions.\n  * NOTE: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n* A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n  * Not a woman of childbearing potential (WOCBP) OR\n  * A WOCBP who is using a highly effective contraceptive method (failure rate of \\\u003C1% per year), or is abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) during the intervention period and for at least 120 days after the last dose of study drug. The investigator should evaluate the potential for contraceptive method failure (i.e., noncompliance, recently initiated) in relationship to the first dose of study drug. See contraceptive guidance in Section 5.1.4 of the protocol.\n* Participants who are HBsAg positive are eligible if they have received HBV anti-viral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization. Note: Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy after completion of study intervention.\n\nHepatitis B screening tests are not required unless:\n\n* Known history of HBV infection\n* As mandated by local health authority\n\n  * Participants with a history of HCV infection are eligible if HCV viral load is undetectable at screening. Note: Participants must have completed curative anti-viral therapy at least 4 weeks prior to randomization.\n\nHepatitis C screening tests are not required unless:\n\n* Known history of HCV infection\n* As mandated by local health authority\n\n  * HIV-infected participants are eligible but must have well-controlled HIV on anti-retroviral therapy (ART), defined as:\n* Participants on ART must have a CD4+ T-cell count ≥350 cells\u002Fmm3 at screening.\n* Participants on ART must have achieved and maintained virologic suppression defined as confirmed HIV RNA level below 50 or the LLOQ (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks before screening.\n* It is advised that participants must not have had any AIDS-defining opportunistic infections within the past 12 months before study entry (Day 1\u002Frandomization).\n* Participants on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks before study entry (Day 1\u002Frandomization) and agree to continue ART throughout the study.\n* Note: HIV screening testing is not required unless mandated by local health authority.\n\n  * As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study\n\nExclusion Criteria:\n\n* Current lung cancer is \\\u003C1 cm or \\> 4 cm in size or is stage II, III, or IV.\n* Patients with tumors that are known to harbor actionable EGFR mutations.\n* Prior chemotherapy, radiation therapy, or immunotherapy for the treatment of this lung cancer.\n* Has a known active additional malignancy that is progressing or has required active treatment within the past 2 years. NOTE: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma in situ, cervical cancer in situ) that have undergone potentially curative therapy are not excluded. Participants with low-risk early-stage prostate cancer (T1-T2a, Gleason score ≤6, and PSA \\\u003C10 ng\u002FmL) either treated with definitive intent or untreated in active surveillance with stable disease are not excluded.\n* Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).\n* Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed.\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.\n\n  * Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to randomization.\n* Has had an allogenic tissue\u002Fsolid organ transplant.\n* Has severe hypersensitivity (≥Grade 3) to pembrolizumab and\u002For any of its excipients.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n* Has a history of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n* Has an active infection requiring systemic therapy.\n* Has active TB (Bacillus Tuberculosis) infection.\n* HIV-infected participants with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.","ALL","18 Years",{"count":19,"type":20},244,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","A randomized trial of adjuvant Pembrolizumab following surgical resection versus observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm.\n\nPatients will be randomized (1:1) 4-12 weeks following surgery to either:\n\n* Arm A: Pembrolizumab 400 mg every 6 weeks × 9 cycles\n* Arm B: Observation\n\nStratification factors will include: PD-L1 TPS (\\\u003C50% vs. ≥50%), and tumor size (1-2 cm vs. \\>2-4 cm)",[26],"NSCLC, Stage I","RECRUITING","2026-04-30",{"date":30,"type":31},"2026-05-05","ACTUAL",{"date":33,"type":31},"2020-05-05",{"date":35,"type":20},"2028-04-08",{"name":37,"class":38},"Greg Durm, MD","OTHER",13,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":50,"conditions":51,"keywords":59,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100617831","phase-2-a-study-of-bio-300-and-thoracic-radiation-therapy-in-people-with-non-small-cell-lung-cancer-and-interstitial-lung-disease-100617831","NCT07323732","A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease","A Phase II Study of BIO 300 to Reduce the Toxicity of Thoracic Radiotherapy for Patients With Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease (BREATHE)","Inclusion Criteria:\n\n* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. - Patient age ≥ 18 at time of consent\n* Stage I - II NSCLC (as per the American Joint Commission on Cancer (AJCC) 8th edition)\n\n  ° Pathologically proven diagnosis of cancer is strongly recommended but is not required if the risk of biopsy is unacceptable. If pathological evidence is not available, there must be clinical evidence for NSCLC and multidisciplinary consensus for treatment.\n* Interstitial Lung Disease diagnosis (one of the below)\n\n  * ILD as diagnosed and managed by a pulmonologist\n  * ILD based on diagnostic imaging criteria and abnormal DLCO\n  * ILD as a result of connective tissue diseases (e.g., polymyositis\u002Fdermatomyositis, rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, scleroderma, mixed connective tissue disease)\n* ECOG performance status of 0 - 3\n* Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrhoeic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n  * Women \\\u003C50 years of age would be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n  * Women ≥50 years of age would be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\>1 year ago, had chemotherapy-induced menopause with last menses \\>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).\n* Life expectancy of at least 6 months\n\nExclusion Criteria:\n\n* Previous thoracic radiation\n* History of pneumonectomy\n* Major surgical procedure (e.g. intra-cranial, intra-thoracic, intra-abdominal, or intra-pelvic) within 28 days prior to enrollment.\n* Severe concurrent illness that may preclude timely completion of thoracic radiation or study procedures\n* Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.\n* ILD exacerbation requiring hospitalization in the last 30 days\n* Poorly controlled cardiac arrhythmias not responding to medical therapy or a pacemaker\n* Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential unless they are willing to employ a highly effective non-estrogen based contraception from screening to 30 days after the last dose of BIO 300 or to abstain from sexual intercourse during these time periods.\n\n  1. Effective method of non-estrogen-based contraception: condom and a diaphragm, condom and intrauterine device, condom and Depo-Provera, condom and Nexplanon, or condom and progesterone mini-pill\n  2. Women who have been off estrogen contraceptives for a minimum 5 days prior to the first scheduled day of study intervention dosing are eligible.\n* Concomitant medications:\n\n  1. Any investigational anticancer therapy.\n  2. Planned concurrent chemotherapy or immunotherapy\n  3. Biologic drugs targeting the immune system (e.g. TNFα blockers, anakinra, rituximab, abatacept, tocilizumab) planned to be use concurrently with BIO 300",{"count":48,"type":20},25,[23],"The purpose of this study to find out whether giving BIO 300 in combination with thoracic radiation therapy is effective in preventing pneumonitis in people with non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD).",[52,26,53,54,55,56,57,58],"NSCLC","NSCLC Stage II","Non Small Cell Lung Cancer","Non-small Cell Lung Cancer Stage I","Non-small Cell Lung Cancer Stage II","Interstitial Lung Disease","Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)",[54,60,61,52,62,53,57,58,63,64],"Non Small Cell Lung Cancer Stage I","Non Small Cell Lung Cancer Stage II","NSCLC Stage I","Memorial Sloan Kettering Cancer Center","25-310","2026-03-02",{"date":67,"type":31},"2026-03-03",{"date":69,"type":31},"2026-01-06",{"date":71,"type":20},"2029-01-06",{"name":63,"class":38},7,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":48},"100551999","a-study-to-describe-the-diagnostic-and-therapeutic-path-of-patients-with-nsclc-in-early-stage-and-locally-advanced-100551999","NCT06467383","A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced","Key-Early","Inclusion Criteria:\n\n1. Patients with stage I-III NSCLC who have received curative surgery or radiotherapy between January 2018 and June 2019 with available follow-up through January 2021\n2. Adult patients (aged ≥ 18 years) at the moment of diagnosis\n3. Patients (or their legally acceptable representatives) must have signed and dated the Informed Consent form; privacy Form (ICF). In case of deceased or untraceable patient the investigator before collecting data shall demonstrate and report all necessary measures adopted to contact the patient.\n\nExclusion Criteria:\n\n1. Patients without availability of medical charts or information required\n2. Enrollment in studies imposing a specific patient's management strategy which does not correspond to the site's normal clinical practice.",{"count":82,"type":20},600,"OBSERVATIONAL","This is a non-interventional, retrospective observational study to improve knowledge regarding the diagnosis and treatments of patients who have\u002Fhad non-small cell lung cancer (NSCLC), either early stage (stage I-II).",[86,52,87,26],"Non-small Cell Lung Cancer","NSCLC, Stage III",[89,90,91,92],"NSCLC early stage","NSCLC locally advanced","retrospective observational study","Real-World Evidence","2025-01-13",{"date":95,"type":31},"2025-01-14",{"date":97,"type":31},"2024-06-25",{"date":99,"type":20},"2025-06-24",{"name":101,"class":102},"MSD Italia S.r.l.","INDUSTRY",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100547145","pulmonary-watershed-topographic-map-navigation-for-lung-nodule-resection-100547145","NCT06404164","Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection","Artificial Intelligence Pulmonary Watershed Terrain Navigation System for Lung Nodule Localization and Lung Function Preservation","Inclusion Criteria:\n\n1. \\\u003C1cm CTR≤0.75; \\\u003C1.5cm CTR≤0.5; \\\u003C2cm CTR≤0.25 Lung nodules\n2. The tumor center is located in the peripheral 2\u002F3 area of the lung field\n3. Preoperative analysis and planning of watershed by 3D reconstruction\n4. Clinically assessed as cT1aN0M0 stage IA1\u002FcT1bN0M0 stage IA2 (eighth edition), clinically resectable\n\nExclusion Criteria:\n\n1. No surgical video, no postoperative gross specimen and related distance measurement records\n2. The incision edge does not exceed the target nodule diameter from the nodule edge\n3. The resection range exceeds 50% of the preoperative planning\n4. Postoperative pathological staging non-pT1aN0M0 IA1 stage\u002FpT1bN0M0 IA2 stage (eighth edition)\n5. Any situation where the investigator feels the need for extended resection\n6. Patients with chronic diseases (such as COPD, pulmonary fibrosis, silicosis) that can cause loss of lung function in patients at risk of progression or potential progression",{"count":111,"type":20},3000,[113],"NA","A method of ICG counterstaining localization under target artery occlusion without cutting，It's a new method of localization of small pulmonary nodules.",[116,117,26],"Pulmonary Function Assessment","Disease Free Survival",[119,120],"Watershed Analysis","wedge resection","2024-05-04",{"date":123,"type":31},"2024-05-08",{"date":125,"type":31},"2022-01-30",{"date":127,"type":20},"2027-12-30",{"name":129,"class":38},"Guangdong Provincial People's Hospital",1,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":21,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":130},"100491999","phase-2-osimertinib-therapy-after-resection-in-high-risk-stage-i-egfrm-nsclc-ostar-100491999","NCT05686434","Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)","Efficacy and Safety of Osimertinib Adjuvant Therapy in High-risk Stage I EGFRm NSCLC After Complete Resection(OSTAR): a Prospective, Single-arm Study","Inclusion Criteria:\n\n1. The subject will voluntarily sign the informed consent in person, and provide the informed consent before any specific study procedures;\n2. Male and female, ≥18 years old;\n3. Primary non-squamous NSCLC confirmed histologically by the central laboratory;\n4. Brain imaging examinations should be performed before surgery or enrollment;\n5. The patient was clinically confirmed as stage I by imaging, and was staged according to the eighth edition of TNM lung cancer;\n6. As confirmed by the central laboratory, the tumor contains one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), alone or in conjunction with other EGFR mutations, including T790M;\n7. The primary NSCLC must be completely resected by surgery, and all lesions must be removed at the end of the surgery.All surgical margins must be negative. Lobectomy can be done with open surgery or thoracoscopic (VATS);\n8. Central laboratory pathology confirmed solid and\u002For micropapillary component ≥10%, or STAS;\n9. The interval from operation to adjuvant Osimertinib treatment is no more than 10 weeks;\n10. WHO physical status score is 0\\~1;\n11. Paraffin-embedded sections (10-15 sheets), or wax blocks or fresh frozen tissue for surgical resection of the lesion should be provided;\n12. At least 2 weeks prior to initiation of the study drug, female subjects should be using highly effective contraceptive methods, pregnancy tests must be negative, and there must be no ongoing breastfeeding prior to initiation of the drug, or else one of the following criteria must be met at the time of screening to demonstrate the possibility of non-fertility:\n\n    * Postmenopausal was defined as over 50 years of age and amenorrhea for at least 12 months after cessation of all exogenous hormone therapy.\n    * Women under 50 should be considered to have stopped menstruating if they have stopped menstruating for 12 months or more after stopping exogenous hormone therapy and their LH and FSH levels are within the agency's postmenopausal range.\n13. Irreversible surgical sterilization recorded by hysterectomy, bilateral oophorectomy or bilateral salpingectomy, but not tubal ligation;Male subjects must be willing to use barrier contraception.\n\nExclusion Criteria:\n\n1. Exposure to other antitumor therapies before enrollment;\n2. Patients who only received segmental resection and wedge resection;\n3. History of other malignancies, other than non-melanoma skin cancer, carcinoma in situ or other solid tumors that have been effectively treated, and the treating physician has determined that there is no evidence of disease recurrence for 5 years after treatment;\n4. Evidence of any severe or uncontrolled systemic disease, including uncontrolled hypertension and active bleeding, any condition that the investigator considers to be detrimental to patient participation in the study or to adherence to the protocol, or active infections including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV). Omission requirement for screening chronic diseases;\n5. Any of the following cardiac criteria:\n\n   * QTc values obtained using screening clinic ECG machines mean resting corrected QT interval (QTc) \\> 470 milliseconds from 3 electrocardiogram (ECG) tests,\n   * Any abnormalities in rhythm, conduction, or morphology of a clinically significant resting ECG, such as left bundle branch block, third degree heart block, and second degree heart block.\n   * Any factors that increase the risk of prolonged QTc or arrhythmia events, such as heart failure, hypokalemia, congenital long QT syndrome, sudden unexplained death under 40 years of age in a first-degree relative or any concomitant medication known to prolong the QT interval.\n6. Any evidence of prior history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia requiring steroid treatment, or active interstitial lung disease;\n7. Lack of adequate bone marrow reserve or organ function (demonstrated by any of the following laboratory values: absolute neutrophil count \\\u003C1.5×10⁹\u002FL;Platelet count \\\u003C100×10⁹\u002FL;Hemoglobin \\\u003C90 g\u002FL;Alanine aminotransferase \\> 2.5 ULN; Aspartate aminotransferase \\>2.5 times ULN;Total bilirubin \\> 1.5 ULN;Serum creatinine \\>1.5 ULN with creatinine clearance \\\u003C50 mL\u002Fmin \\[as measured or calculated by Cockcroft and Gault formulas\\] - creatinine clearance only needs to be confirmed when creatinine \\>1.5 ULN);\n8. History of hypersensitivity to active or inactive excipients of Osimertinib or drugs with similar chemical structures or classes to ocitinib;\n9. Uncontrolled nausea and vomiting, chronic gastrointestinal illness, inability to swallow formulated drugs, or prior major bowel resection that prevents adequate absorption of Osimertinib;\n10. Any evidence of corneal injury confirmed by ophthalmic examination through slit lamp evaluation;\n11. The patient is pregnant or nursing;\n12. History of allergy to ocitinib active or inactive excipients or drugs similar in chemical structure or class to Osimertinib;\n13. If the patient is unlikely to comply with study procedures, restrictions, and requirements, the investigator judges that the patient should not participate in the study.",{"count":139,"type":20},65,[23],"This is a prospective, open, single-center, single-arm phase II clinical study with common EGFR-sensitive mutations (Ex19del and L858R) identified in the central laboratory.To evaluate the efficacy and safety of adjuvant Osimertinib therapy in completely resected stage I non-squamous non-small cell lung cancer (NSCLC) with high-risk factors (solid and\u002For micropapillary component ≥10%, and\u002For airway spread).",[26],"2023-01-06",{"date":145,"type":31},"2023-01-17",{"date":147,"type":31},"2022-10-14",{"date":149,"type":20},"2029-10-14",{"name":151,"class":38},"Tianjin Medical University Cancer Institute and Hospital"]